Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Human pharmacolinetics of the daunorubicin-DNA complex

An alternative view of the lysosomotropic theory

  • 17 Accesses

  • 1 Citations

Summary

Plasma kinetics and urinary excretion of daunorubicin (DNR) and its active metabolite, daunorubicinol (DNR-ol) were studied in 15 leukemic patients after a 4-h infusion of 75 mg DNR/m2 either as the free drug or as a complex with DNA. The data obtained after infusion of the DNR-DNA complex were compared with the data obtained after infusion of the free drug. The DNR plasma levels were found to be higher during the 2 h following the infusion of the complex; the levels of DNR-ol were only higher for a few minutes after infusion.

Kinetic analysis showed that complexing with DNA does not fundamentally modify the three-compartment model described for DNR. Only quantitative modifications were observed: a marked lengthening of the α-phase and a shortening of the γ-phase. Urinary excretion of DNR and DNR-ol was increased after infusion of the complexed drug, in relation to the persistence of higher plasma levels.

The data recorded in this work do not confirm the lysosomotropic mechanism postulated for the DNR-DNA complex, but show a delayed distribution of DNR, which is progressively released by dissociation of the circulating DNR-DNA complex, as previously demonstrated in rabbits infused under same conditions.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Andersson, B., Andersson, I., Beran, M., Ehrsson, H., Ecksborg, S.: Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother. Pharmacol. 2, 15 (1979)

  2. 2.

    Arlandini, E., Vigevani, A., Arcamone, F.: Interaction of new derivatives of daunomycin and adriamycin with DNA. Farmaco [Sci.] 32, 315 (1977)

  3. 3.

    Bachur, N. R.: Adriamycin-daunorubicin cellular pharmacodynamics. Biochem. Pharmacol. (Suppl.) 2, 207 (1974)

  4. 4.

    Bernard, J., Weil, M., Jacquillat, C.: Treatment of acute granulocytic leukemia. Annu. Rev. Med. 25, 39 (1974)

  5. 5.

    Cornu, G., Michaux, J. L., Sokal, G., Trouet, A.: Daunorubicin-DNA: further trials in acute non-lymphocytic leukemia. Eur. J. Cancer 10, 695 (1974)

  6. 6.

    Das, G. C., Dasgupta, S., Dasgupta, N. N.: Interaction of nogalomycin with DNA. Biochim. Biophys. Acta 353, 274 (1974)

  7. 7.

    Ferrant, A., Hulhoven, R., Bosly, A., Cornu, G., Michaux, J. L., Sokal, G.: Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute non-lymphocytic leukemia, and bronchogenic carcinoma. Cancer Chemother. Pharmacol. 2, 67 (1979)

  8. 8.

    Huffman, D. H., Bachur, N. R.: Daunorubicin metabolism in acute non-lymphocytic leukemia. Clin. Pharmacol. Ther. 13, 895 (1972)

  9. 9.

    Hulhoven, R.: Daunorubicin, daunorubicinol and DNA plasma kinetics after i.v. administration of daunorubicin-DNA complex in the rabbit. Biomedicine 29, 164 (1978)

  10. 10.

    Hulhoven, R., Desager, J. P.: Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography. J. Chromatogr. 125, 369 (1976)

  11. 11.

    Hulhoven, R., Desager, J. P.: HPLC determination of daunorubicin and daunorubicinol in human plasma. Biomedicine 27, 102 (1977)

  12. 12.

    Hulhoven, R., Desager, J. P., Sokal, G., Harvengt, C.: Plasma levels and biotransformation of infused daunorubicin and daunorubicin-DNA complex in rabbits: a preliminary report. Eur. J. Cancer 13, 1065 (1977a)

  13. 13.

    Hulhoven, R., Desager, J. P., Sokal, G., Harvengt, C.: Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: a preliminary report. Arch. Int. Pharmacodyn. Ther. 226, 344 (1977b)

  14. 14.

    Seeber, S., Brucksch, K. P., Seeber, B., Schmidt, C. G.: Cytostatic efficacy of DNA complexes of adriamycin, daunomycin and actinomycin D. I. Comparison studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leucocytes. Z. Krebsforsch. 89, 75 (1977)

  15. 15.

    Sokal, G., Trouet, A., Michaux, J. L., Cornu, G.: DNA-daunorubicin complex: preliminary trials in human leukaemia. Eur. J. Cancer 9, 391 (1973)

  16. 16.

    Takanashi, S., Bachur, N. R.: Daunorubicin metabolites of human urines. J. Pharmacol. Exp. Ther. 195, 41 (1975)

  17. 17.

    Trouet, A., Deprez-Decampeneere, D., de Duve, C.: Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature, New Biol. 239, 110 (1972)

Download references

Author information

Correspondence to R. Hulhoven.

Additional information

Chargé de recherches du Fonds National de la Recherche Scientifique of Belgium

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hulhoven, R., Sokal, G. & Harvengt, C. Human pharmacolinetics of the daunorubicin-DNA complex. Cancer Chemother. Pharmacol. 3, 243–247 (1979). https://doi.org/10.1007/BF00254739

Download citation

Keywords

  • Cancer Research
  • Plasma Level
  • Urinary Excretion
  • Active Metabolite
  • Kinetic Analysis